LAWS H W
Can Med Assoc J. 1964 Aug 15;91(7):325-30.
Four peripheral vasodilators - tolazoline HCl (Priscoline), nicotinic acid, nicotinyl alcohol (Roniacol), and nylidrin HCl (Arlidin)-were studied in 203 patients over a 13-year period as treatment for macular degenerative changes in the eye.Visual acuity was improved or maintained in 87%. Excellent results were obtained in the treatment of macular edema following cataract surgery and in older patients with diabetic retinopathy. In 126 out of 145 patients with senile macular degeneration, improvement or stabilization was obtained.For all the types of macular degeneration, nylidrin HCl was the most effective of the drugs studied and had the fewest side effects.A recent report based upon animal experiments advises against the use of peripheral vasodilators in degenerative arterial diseases of the eye; however, the assumption made therein that blood volume is a measure of blood flow cannot be accepted. Peripheral vasodilator therapy, which long-term clinical study has shown to be valuable in the treatment of macular degeneration, should not therefore be denied to these patients.
在13年期间,对203例患者使用四种外周血管扩张剂——盐酸妥拉唑啉(普里斯科林)、烟酸、烟醇(罗尼阿科)和盐酸尼立替林(阿尔利丁)——治疗眼部黄斑变性改变。87%的患者视力得到改善或维持。在治疗白内障手术后的黄斑水肿以及老年糖尿病性视网膜病变患者中取得了优异的效果。在145例老年性黄斑变性患者中,有126例病情得到改善或稳定。对于所有类型的黄斑变性,盐酸尼立替林是所研究药物中最有效的,且副作用最少。最近一份基于动物实验的报告建议不要在眼部退行性动脉疾病中使用外周血管扩张剂;然而,其中关于血容量是血流量指标的假设是不能被接受的。长期临床研究表明外周血管扩张剂疗法在治疗黄斑变性方面具有价值,因此不应拒绝为这些患者使用该疗法。